ACAD — Acadia Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $4.34bn
- $3.48bn
- $1.07bn
Brief: Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP- Aerovironment, Cisco, Dell Technologies
Brief: Acadia Pharmaceuticals expects To Deliver Over $1 Billion In Net Sales in FY2025
Brief: Acadia Pharmaceuticals reports inducement grants under Nasdaq listing rule
US appeals court confirms patent validity of Acadia's Parkinson's drug
Brief: U.S. Court Of Appeals For The Federal Circuit Affirms Prior Delaware District Court Rulings In Favor Of Acadia In Nuplazid® (Pimavanserin) Composition Of Matter Patent
Brief: Delaware District Court Rules In Favor Of Acadia In Nuplazid Formulation Patent Litigation
U.S. STOCKS ON THE MOVE-Netflix, Acadia Pharma, CoreWeave
Acadia Pharma soars after favorable court ruling in patent dispute
Brief: Acadia Pharmaceuticals Inc Files For Offering Of Up To 43.6 Million Shares Of Common Stock By The Selling Stockholders - SEC Filing
Acadia Pharmaceuticals Inc Reports Results For The Quarter Ended March 31: Earnings Summary
Brief: Acadia Pharmaceuticals Q1 EPS USD 0.11 Vs. IBES Estimate USD 0.11
Soleno jumps as analysts say US nod for rare disease drug transforms treatment options (updated)
Brief: Saniona, Acadia Announce Initial Positive Results From ACP-711 Phase 1 Study
Acadia Pharmaceuticals Inc Reports Results For The Quarter Ended December 31: Earnings Summary
Brief: Acadia Pharmaceuticals Q4 EPS USD 0.86 Vs. IBES Estimate USD 0.22
Brief: Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
Brief: Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome
Acadia Pharmaceuticals to be part of S&P SmallCap 600, shares rise